5 articles
Hologen, co-founded by former Google CEO Eric Schmidt, is raising $150M at an $850M valuation, combining AI drug development with a $430M MeiraGTx gene therapy partnership for Parkinson's disease.
The LIGAND-AI consortium launched with over 60 million euros in EU funding, bringing 18 partners led by Pfizer and the SGC together to generate open datasets of protein-ligand interactions for training AI drug discovery models.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab in South San Francisco, combining Lilly's pharmaceutical expertise with NVIDIA's BioNeMo platform and Blackwell-powered supercomputing to reinvent drug discovery.
Insilico Medicine announced an $888M oncology partnership with Servier days after raising $292M in the largest Hong Kong biotech IPO of 2025, with shares surging 45% on debut.
Insilico Medicine and Hisun Pharma nominated a preclinical candidate in just 8 months using the Pharma.AI platform, dramatically compressing a process that typically takes 2.5 to 4 years in traditional drug discovery.